JBIO

Jade Biosciences, Inc.

NasdaqCMUSDEQUITY DELAYED

21.34

▲ 0.11 (0.52%)

MARKET · —

Price

Open

21.45

Prev close

21.23

Day high

22.12

Day low

21.13

Volume

564.86K

Market cap

—

P/E (TTM)

—

52W range

6.91 – 28.00

Trailing performance

Price return · vs SPY

Returnvs SPY

-13.64% -12.3%

+8.77% +5.0%

-9.04% -12.1%

+49.54% +38.5%

YTD

+38.30% +26.0%

+211.53% +191.5%

-95.93% -170.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

22.79

-6.37% from price

SMA 20

21.65

-1.45% from price

SMA 50

20.80

+2.61% from price

SMA 100

20.99

+1.68% from price

SMA 200

17.46

+22.25% from price

EMA 12

22.25

-4.09% from price

EMA 26

21.75

-1.88% from price

EMA 50

21.19

+0.71% from price

RSI (14)

47.8

Neutral

MACD (12,26,9)

0.50

Hist -0.10

ATR (14)

1.57

7.35% of price

Realised vol 30D

58.5%

Annualised

Bollinger upper

24.82

20, 2σ

Bollinger lower

18.49

20, 2σ

50 / 200 cross

Golden

20.80 vs 17.46

Trend bias

Above 200

+22.25%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.46

More volatile than market

Correlation to SPY

0.25

Largely independent

Realised vol 30D

58.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-44.2%

Peak to trough

Max drawdown 5Y

-99.4%

Peak to trough

ATR 14

1.57

7.35% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 21.34

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

JBIO · links out to the publisher

Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating MT Newswires · 12d ago Jade Biosciences' Q2 Loss Narrows MT Newswires · 12d ago Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics MT Newswires · 51d ago Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? Insider Monkey · 53d ago Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors GlobeNewswire · 57d ago Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · 78d ago Jade Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire · 80d ago Jade Biosciences Announces Proposed Underwritten Public Offering GlobeNewswire · 80d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.